Molecular landscape and site of metastasis in PDAC.

S Rahman, Y Baca, H Singh, J Xiu, AB Mallick… - 2024 - ascopubs.org
4159 Background: More than 50% of patients with Pancreatic ductal adenocarcinoma
(PDAC) have metastatic disease at the time of diagnosis and liver is the most common site of …

[HTML][HTML] The identification of liver metastasis-and prognosis-associated genes in pancreatic ductal adenocarcinoma

H Luan, Y He, T Zhang, Y Su, L Zhou - BMC cancer, 2022 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is an often fatal malignancy with an
extremely low survival rate. Liver metastasis, which causes high mortality, is the most …

Comprehensive genomic analysis in metastatic pancreatic ductal adenocarcinoma (PDAC).

HL Wong, M Jones, P Eirew, J Karasinska… - 2016 - ascopubs.org
285 Background: In the absence of defined tumor molecular subtypes and validated
predictive markers, PDAC has been largely treated as a single disease. Recent studies of …

The proteomic landscape of pancreatic ductal adenocarcinoma liver metastases identifies molecular subtypes and associations with clinical response

HCH Law, D Lagundžin, EJ Clement, F Qiao… - Clinical Cancer …, 2020 - AACR
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease that can
be separated into distinct subtypes based on molecular signatures. Identifying PDAC …

[引用][C] 1644P The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer

G Yao, Q Zhang, Y Tan, Q Duan… - Annals of …, 2023 - annalsofoncology.org
Background Pancreatic ductal adenocarcinoma (PDAC) has been found to metastasize in
more than 50% of patients at the time of their initial diagnosis. This is considered to be the …

Abstract B81: gene expression analysis demonstrates prognostic subtypes in metastatic pancreatic ductal adenocarcinoma (PDAC)

H Wong, JM Karasinska, M Jones, P Eirew… - Cancer …, 2016 - aacrjournals.org
Background: In the absence of defined tumor molecular subtypes and validated predictive
markers, PDAC has been largely treated as a single disease. Recent studies of molecular …

Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC).

A Osipov, EM Blais, J Davelaar, N Moshayedi… - 2022 - ascopubs.org
532 Background: PDAC remains one of the most lethal malignancies following metastatic
presentation, typically to the liver or lung. Previous studies have observed that advanced …

The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response …

HCH Law, EJ Clement, PM Grandgenett… - Clinical Cancer …, 2021 - AACR
We appreciate the comments by Le Large and colleagues regarding our article describing
metastatic pancreatic ductal adenocarcinoma (PDAC) microenvironment subtypes using …

[HTML][HTML] Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways

WJ Ho, R Erbe, L Danilova, Z Phyo, E Bigelow… - Genome biology, 2021 - Springer
Background The majority of pancreatic ductal adenocarcinomas (PDAC) are diagnosed at
the metastatic stage, and standard therapies have limited activity with a dismal 5-year …

Abstract B108: Integrated in vivo dissection of metastatic phenotypes and molecular programs in pancreatic ductal adenocarcinoma

S Karmakar, A Lyulina, X Xiong, YJ Tang, S Lopez… - Cancer Research, 2024 - AACR
The ability of pancreatic ductal adenocarcinoma (PDAC) cells to form tissue destructive
metastases remains a critical impediment to therapy. Metastasis is a complex multistep …